Robert J. Brilon - 23 Feb 2026 Form 4 Insider Report for Iveda Solutions, Inc. (IVDA)

Role
Chief Financial Officer
Signature
/s/ Robert J Brilon
Issuer symbol
IVDA
Transactions as of
23 Feb 2026
Net transactions value
$0
Form type
4
Filing time
25 Feb 2026, 16:30:27 UTC
Previous filing
31 Dec 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Robert J. Brilon filed Form 4 for Iveda Solutions, Inc. (IVDA) on 25 Feb 2026."

Quick Takeaways

  • This page summarizes Robert J. Brilon's Form 4 filing for Iveda Solutions, Inc. (IVDA).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Filing timestamp: 25 Feb 2026, 16:30.

What Changed

  • Previous filing in this sequence was filed on 31 Dec 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BRILON ROBERT J Chief Financial Officer 1744 S. VAL VISTA DRIVE,, STE. 213, MESA /s/ Robert J Brilon 25 Feb 2026 0001221830

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IVDA Options (Right to Buy) Disposed to Issuer $0 +125,000 +454% $0.000000 152,503 29 Dec 2025 Common Stock 125,000 $0.8200 Direct
transaction IVDA Options (Right to Buy) Award $0 +125,000 +454% $0.000000 152,503 23 Feb 2026 Common Stock 125,000 $0.2900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 23, 2026, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $0.29 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

Sponsored